MX2017011981A - Terapias novedosas para cancer. - Google Patents

Terapias novedosas para cancer.

Info

Publication number
MX2017011981A
MX2017011981A MX2017011981A MX2017011981A MX2017011981A MX 2017011981 A MX2017011981 A MX 2017011981A MX 2017011981 A MX2017011981 A MX 2017011981A MX 2017011981 A MX2017011981 A MX 2017011981A MX 2017011981 A MX2017011981 A MX 2017011981A
Authority
MX
Mexico
Prior art keywords
cancer
novel therapies
treatment
relates
diazepan
Prior art date
Application number
MX2017011981A
Other languages
English (en)
Other versions
MX377817B (es
Inventor
Richardson Peter
Festuccia Claudio
Mary Walling Jacqueline
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of MX2017011981A publication Critical patent/MX2017011981A/es
Publication of MX377817B publication Critical patent/MX377817B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se relaciona a 6-{4-[1-(propan-2-il)-piperidin-4-il]- 1,4-diazepan-1-il}-N-(piridin-4-il)piridin-2-carboxamida, o una sal farmacéuticamente aceptable de la misma, para el uso en el tratamiento de cánceres del CNS. La invención también se relaciona a tratamientos de combinación con irradiación y/o un agente quimioterapéutico para el uso en el tratamiento de cáncer.
MX2017011981A 2015-04-02 2016-04-01 Terapias novedosas para cancer. MX377817B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562141980P 2015-04-02 2015-04-02
PCT/IB2016/051880 WO2016157149A1 (en) 2015-04-02 2016-04-01 Novel therapies for cancer

Publications (2)

Publication Number Publication Date
MX2017011981A true MX2017011981A (es) 2018-01-10
MX377817B MX377817B (es) 2025-03-11

Family

ID=55702039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011981A MX377817B (es) 2015-04-02 2016-04-01 Terapias novedosas para cancer.

Country Status (18)

Country Link
US (1) US11311552B2 (es)
EP (1) EP3277284B1 (es)
JP (1) JP6927882B2 (es)
KR (1) KR20170132314A (es)
CN (2) CN112569242A (es)
AU (1) AU2016242118B2 (es)
BR (1) BR112017019437A2 (es)
CA (1) CA2979167A1 (es)
DK (1) DK3277284T3 (es)
EA (1) EA037555B1 (es)
ES (1) ES2826558T3 (es)
HU (1) HUE051341T2 (es)
IL (1) IL254149A0 (es)
MX (1) MX377817B (es)
PL (1) PL3277284T3 (es)
PT (1) PT3277284T (es)
SG (2) SG11201707429VA (es)
WO (1) WO2016157149A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JP6927882B2 (ja) 2015-04-02 2021-09-01 プロキシマジェン，リミティド ライアビリティ カンパニー 癌の新治療法
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
GB201703907D0 (en) * 2017-03-10 2017-04-26 Proximagen Ltd Novel therapies for cancer
WO2020222189A1 (en) 2019-05-02 2020-11-05 Proximagen, Llc Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
WO2020222190A1 (en) 2019-05-02 2020-11-05 Proximagen, Llc Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
FR2769913B1 (fr) 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AU2001268718B2 (en) 2000-06-29 2006-01-05 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
WO2003082855A1 (en) 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
EP1608318A4 (en) * 2003-03-27 2009-07-29 Univ Emory CXCR4 ANTAGONISTS AND METHOD OF USE
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
FR2854633B1 (fr) 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
US7491735B2 (en) 2003-12-11 2009-02-17 Genzyme Corporation Chemokine receptor binding compounds
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
JP2008530216A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
CA2598458A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
AU2006214378A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006130426A2 (en) 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
PE20071144A1 (es) 2006-03-21 2008-01-10 Schering Corp COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3)
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
AR061975A1 (es) 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
KR101436179B1 (ko) 2006-09-02 2014-09-01 메르크 파텐트 게엠베하 반응성 메소젠의 배향을 위한 입자 빔 방법
MX2009002960A (es) 2006-09-21 2009-06-26 Activx Biosciences Inc Inhibidores de serina hidrolasa.
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
EP2094688A1 (en) 2006-12-22 2009-09-02 Schering Corporation Heterocyclic compounds with cxcr3 antagonist activity
EP2121613A2 (en) 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
WO2008121065A1 (en) 2007-03-30 2008-10-09 Astrazeneca Ab Novel pyrrolidine derivatives as antagonists of the chemokine receptor
EP2231636B1 (en) 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
EP2262494A2 (en) * 2008-02-29 2010-12-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth by an inhibitor of vasculogenesis
KR101701367B1 (ko) 2008-11-04 2017-02-02 케모센트릭스, 인크. Ｃｘｃｒ７의 모듈레이터
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
WO2012047339A2 (en) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
MX2015008010A (es) * 2012-12-20 2016-04-26 qing-bin Lu Compuestos radiosensabilizadores para usarse en combinacion con radiacion.
JP6927882B2 (ja) 2015-04-02 2021-09-01 プロキシマジェン，リミティド ライアビリティ カンパニー 癌の新治療法
GB201604213D0 (en) 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
GB201703907D0 (en) 2017-03-10 2017-04-26 Proximagen Ltd Novel therapies for cancer

Also Published As

Publication number Publication date
HK1245120A1 (en) 2018-08-24
BR112017019437A2 (pt) 2018-05-02
EP3277284B1 (en) 2020-08-05
CN107438437A (zh) 2017-12-05
EA037555B1 (ru) 2021-04-13
PT3277284T (pt) 2020-11-11
US20180078563A1 (en) 2018-03-22
ES2826558T3 (es) 2021-05-18
AU2016242118A1 (en) 2017-10-05
PL3277284T3 (pl) 2021-03-08
SG11201707429VA (en) 2017-10-30
JP2018510154A (ja) 2018-04-12
AU2016242118B2 (en) 2021-07-08
JP6927882B2 (ja) 2021-09-01
IL254149A0 (en) 2017-10-31
CA2979167A1 (en) 2016-10-06
EP3277284A1 (en) 2018-02-07
CN107438437B (zh) 2021-01-01
SG10201909188XA (en) 2019-11-28
MX377817B (es) 2025-03-11
HUE051341T2 (hu) 2021-03-01
EA201791953A1 (ru) 2018-01-31
CN112569242A (zh) 2021-03-30
WO2016157149A1 (en) 2016-10-06
DK3277284T3 (da) 2020-10-26
WO2016157149A9 (en) 2016-12-08
KR20170132314A (ko) 2017-12-01
US11311552B2 (en) 2022-04-26

Similar Documents

Publication Publication Date Title
SG10201909188XA (en) Novel therapies for cancer
PH12017550063A1 (en) Combination therapies for treating cancers
PH12015502091A1 (en) Cdc7 inhibitors
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
PH12017500881B1 (en) Aurora a kinase inhibitor
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
EP4656246A3 (en) Combination therapies for the treatment of cancer
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
SG10201902664RA (en) Combination therapy for treating cancer
PH12016502354A1 (en) Pharmaceutical composition
MX2018001289A (es) Terapias de combinacion para el tratamiento del cancer.
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
PH12018502360A1 (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
MX2019010679A (es) Usl-311 para uso en el tratamiento de cancer.
PT3362056T (pt) Compostos de aminotioléster ou seus sais farmaceuticamente aceitáveis, para utilização no tratamento de cancro
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
NZ722296A (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
MX2019003002A (es) Terapias de combinacion que usan derivados de indazolilbenzamida para el tratamiento del cancer.
JOP20170159A1 (ar) علاجات توليفية لعلاج السرطانات
MX2018013863A (es) Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer.